Improving global health outcomes and sustainable financial value

Clinigen is dedicated to solving an increasingly global healthcare problem - ensuring patients around the world have access to the critical medicines they need. Our mission to deliver the Right Medicine, to the Right Patient, at the Right Time is at the heart of everything we do. This mission gives Clinigen a clear purpose - to ultimately improve health outcomes and improve the lives of patients accessing our medicines whilst delivering greater value and sustainability to our stakeholders. Our capability to carefully control and manage a medicine across the world’s pharmaceutical markets and overcome barriers to its availability maximises its reach and maximises the value of the medicine to its owner.

Our business operates to the highest standards of governance and compliance. We recognise the value of having a clear purpose supported by a strong culture of ethics, quality, and patient safety. We are responsible, transparent, and focused on making a positive impact across our value chain, the environment and society.

Our ability to impact and contribute to the sustainability agenda continues to evolve as we continue to ‘join-the-dots’ across our businesses to broaden our service and product offering. As a global leader in ethical access to medicines there is an increasing expectation amongst our stakeholders that we contribute, measure, and communicate the impact our strategy has on a range of sustainability issues.

Our track record

Over the past decade our business has transformed, evolved, and dramatically increased its capabilities and reach. Our global footprint now enables us to reach more healthcare professionals and their patients in need of critically-important medicines; we consistently manage and supply hospital medicines to over 120 countries to the highest ethical and regulatory compliant standards, for both licensed and unlicensed situations.

We are the global leader in access to medicines, and as such, Clinigen has consistently translated this business capability into healthy financial returns for our stakeholders. Our business model is core to this success, establishing a global synergistic Services and Products platform that provide high value solutions to unmet and underserved needs for both pharmaceutical and biotechnology companies and healthcare professionals globally.

We have recently undertaken a full review of how our strategy aligns to stakeholder values to ensure that our business model, objectives, and growth plans are clearly aligned to the sustainability agenda (see our materiality assessment for further details).

In 2021, the materiality assessment highlighted global access and reach, alongside sustainable financial returns, as the issues considered most important to our stakeholders. We have used the outcomes to help drive our sustainability plans and targets. For instance, a core objective of our strategy is to become the ‘go to’ global leader in ethical access to difficult to find medicines - we are therefore focused on expanding and deepening our client base with the owners of developing products in Services; and growing and developing our portfolio of exclusive supply agreements in Products to deepen our relationships with healthcare professionals. Delivering upon this objective will enable us to successfully contribute to improved access and reach of medicines throughout the world.

Our continued commitment

I am delighted to announce that the Group recently became a signatory of the United Nations Global Compact (UNGC) and UN Sustainable Development Goals (SDGs). In doing so, it supports and formalises our commitment to sustainability. As a global business, we recognise that corporate sustainability starts with our values and adoption of a principles-based approach to doing business. This means operating in ways that, at a minimum, meet fundamental responsibilities in the areas of human rights, labour, environment, and anti-corruption. Clinigen has always been a responsible business, enacting the same values and principles as set out under the UNGC into our business and culture. By signing up to the UNGC, we will more formally incorporate the Ten Principles of the UN Global Compact into our strategies, policies, and procedures in the future.

Most recently, a cross functional project team has worked hard to develop a clear sustainability framework which is aligned to both our strategy and culture, but also external frameworks, standards, and initiatives such as the UN SDGs and the Sustainability Accounting Standards Board (SASB). As a Group, we know that there is further work to do to ensure we can fully disclose against the Task Force on Climate-Related Financial Disclosures (TCFD) reporting requirements, however, a huge amount of progress has already been made in positioning the business to meet these obligations in the future, as and when they become mandatory for listed entities.

Keeping our stakeholders informed

The Environmental, Social and Governance (ESG) agenda over the past 12 months has significantly gathered pace, partially due to the pandemic. We have used this time to gather, understand and formulate our sustainability framework, approach, and commitments. It is important that we continue to assess and report on progress. We will do this through annual publication of our performance against targets and initiatives within the Annual Report. For investors and analysts, we will update on our progress through trading updates.

These dedicated webpages provide an overview of our sustainability framework and actions we are taking to make a positive contribution across a range of ESG issues considered to be most important to our business and stakeholders.

We always welcome feedback from our stakeholders. If you’d like to get in touch, please contact us via Investor Relations.

Shaun Chilton, Group ceo